Changes in Hong Kong stocks | Waku-B (02256) rose by more than 6%, the self-developed high-selective CSF-1R small molecule inhibitor pimitinib has been approved for listing in Switzerland

The Zhitong Finance App learned that Heyu-B (02256) rose by more than 6%. As of press release, it had risen 3.56% to HK$6.55, with a turnover of HK$15.9727 million.

According to the news, recently, the official website of the Swiss Medicines Agency (Swissmedic) shows that pimicotinib (pimicotinib), a highly selective CSF-1R small molecule inhibitor independently developed by Wakyu Pharmaceutical, has been approved for marketing in Switzerland to treat adult patients with tenosynovial giant cell tumor (TGCT) who may not be suitable for surgical removal. Following approval in China in December 2025 and approval in Canada in June 2026, pimitinib once again made progress in entering overseas markets.

As an oral, highly selective CSF-1R small molecule inhibitor, pimitinib works by targeting the CSF-1/CSF-1R signaling pathway, providing new treatment options for relevant patients. The results of the global Phase III EVER study showed that in terms of objective remission rate (ORR) assessed by the Independent Blind Review Committee (BIRC) based on RECIST 1.1 criteria in week 25, the pimitinib group reached 54.0% and the placebo group 3.2%. The difference was statistically significant. The study also assessed clinical benefit indicators such as patients' physical function and pain, providing a clinical basis for global registration of the product.